SCHEMBL4132553

SCHEMBL4132553

CCOC(=O)c1ccc(COc2cc3ccccc3cc2C=C2SC(Nc3ccc(C(O)C(=O)O)c(F)c3)=NC2=O)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTP4A3 O75365 3/20 0.37
PPIA P62937 2/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 4/20 0.35
ALDH1A1 P00352 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
CISD1 Q9NZ45 1/20 0.35
DHODH Q02127 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
EGFR P00533 1/20 0.33
KDR P35968 1/20 0.33
NPC1 O15118 1/20 0.33
GBA1 P04062 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4132551 1.00 PTP4A3 (0.37) PTP4A3PPIAMEN1KMT2AMAPK1
SCHEMBL4134460 0.91 PTP4A3 (0.36) PTP4A3PPIAMEN1KMT2AMAPK1
SCHEMBL4134464 0.91 PTP4A3 (0.36) PTP4A3PPIAMEN1KMT2AMAPK1
SCHEMBL4634772 0.85 EGFR (0.36) PTP4A3PPIAMEN1KMT2AMAPK1
SCHEMBL4129153 0.83 PTP4A3 (0.46) PTP4A3MEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL4129152 0.83 PTP4A3 (0.46) PTP4A3MEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL4128497 0.82 PTP4A3 (0.47) PTP4A3MEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL4128499 0.82 PTP4A3 (0.47) PTP4A3MEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL4133914 0.79 EGFR (0.39) PPIAMEN1KMT2AMAPTALDH1A1
SCHEMBL4133912 0.79 EGFR (0.39) PPIAMEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ PTP4A3 26/4885PPIA 901/4885MEN1 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.